POMALYST
(pomalidomide)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Multiple myeloma (MM)
    a. Used in combination with dexamethasone
    b. Patient has **ONE** of the following:
        i. Patient has received at least **TWO** prior therapies for multiple myeloma including lenalidomide and a proteasome inhibitor **AND** has demonstrated disease progression on or within 60 days of completion of the last therapy for multiple myeloma
        ii. Patient has received at least **ONE** prior line of therapy including lenalidomide and a proteasome inhibitor **AND** used in combination with daratumumab and hyaluronidase-fihj
2. Kaposi sarcoma (KS) and **ONE** of the following:
    a. AIDS-related Kaposi sarcoma
        i. Patient has failed highly active antiretroviral therapy (HAART)
    b. Patient is HIV-negative

AND ALL of the following:

1. Blood counts for neutropenia, thrombocytopenia, and anemia will be monitored weekly for the first 8 weeks and monthly thereafter
2. Females of reproductive potential **only**: pregnancy has been excluded prior to initiation of therapy and patient will be advised to use 2 reliable methods of contraception during therapy and for 4 weeks after the last dose
3. Males with female partners of reproductive potential **only**: patient will be advised to use a latex or synthetic condom during therapy and for 4 weeks after the last dose, even if they have undergone a successful vasectomy
4. Physician, patient, and pharmacy are registered with the REMS program

BlueCross BlueShield Federal Employee Program

POMALYST
(pomalidomide)

Prior - Approval Limits

Quantity

Diagnosis	Quantity
Multiple myeloma	63 capsules per 84 days **OR**
Kaposi sarcoma	126 capsules per 84 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Multiple myeloma (MM)
2. Kaposi sarcoma (KS)

AND ALL of the following:

1. Blood counts for neutropenia, thrombocytopenia, and anemia will be monitored monthly
2. Females of reproductive potential **only**: patient will be advised to use 2 reliable methods of contraception during therapy and for 4 weeks after the last dose
3. Males with female partners of reproductive potential **only**: patient will be advised to use a latex or synthetic condom during therapy and for 4 weeks after the last dose, even if they have undergone a successful vasectomy

Prior – Approval *Renewal* Limits

Same as above